Maurie Markman, MD

Articles

Real-World Data Grow Increasingly Relevant in Oncology Practice

January 27th 2021

The importance of objectively valid data is well established in clinical medicine. Such data include an accurate recording of a patient’s clinical history; evaluation of signs and symptoms of illness; and measurement of various routine indicators, such as granulocyte and platelet counts, serum glucose, electrolytes, and liver function tests.

PFS Deserves More Than Surrogate Status as a Clinical Trial End Point

January 20th 2021

Although recent benefits do not pertain to all cancers and “cure” remains a relatively uncommon event, oncologists have an increasing number of molecularly targeted and immunotherapeutic strategies to employ based on objectively meaningful clinical trial outcomes.

Dr. Markman on Remaining Questions With HPV- Cervical Cancer

January 18th 2021

Maurie Markman, MD, discusses remaining questions regarding human papillomavirus–negative cervical cancer.

Markman: COVID-19 Takes Science on a Roller-Coaster Ride

January 10th 2021

In a pandemic, the public and its leaders yearn for relatively simple answers that can lead to solutions and forceful actions such as preventing serious infection and hospitalizations, treating active illness, and developing safe and effective vaccines quickly made available to the public.

Real-World Impact of Low-Grade AEs Needs a Closer Look

November 18th 2020

Although PARP inhibitors are generally reasonably well tolerated, certainly compared with platinum and other routinely employed cytotoxic antineoplastic drugs, the majority of patients receiving PARP inhibitors in multiple reported clinical trials reported low-grade nausea and fatigue.

Dr. Markman on the Benefit of PARP Inhibitors in Ovarian Cancer

November 6th 2020

Maurie Markman, MD, discusses the utility of PARP inhibitors in ovarian cancer.

HPV Vaccination Is a Battle That Must Be Won

November 2nd 2020

Despite solid evidence that human papillomavirus vaccination is remarkably effective in preventing persistent infection by HPV types that are known to be responsible for more than 70% to 80% of cervical cancer cases worldwide, this strategy’s utility in substantially reducing the subsequent development of the malignancy itself remained an open question.

Complex Clinical Trial Issues Require an Ethical Balancing Act

October 13th 2020

The fundamental objectivity of major scientifically oriented public health agencies has been called into question, while the issue of what constitutes sufficient evidence for a therapeutic strategy to be considered “standard” is also being challenged.

Technological Advances Come With a Cautionary Note

September 30th 2020

In the realm of medicine, we see enormous opportunities for truly novel technologies to revolutionize the health and welfare of all members of society.

Scramble Over COVID-19 Clinical Trials Holds Lessons for Oncology

September 12th 2020

Because it is likely that COVID-19 will be around for a considerable period of time, it is hoped that all involved in the clinical research establishment can view this experience as a process that needs substantial improvement.

It’s Time to Modernize Genetic Counseling in Oncology

August 14th 2020

Several developments emphasize the increasing clinical relevance of germline testing within the oncology arena and the need for associated genetic counseling.

The Good, the Bad, and the Ugly: Academic Medicine in the Spotlight

July 29th 2020

The coronavirus disease 2019 pandemic has raised the public profile of experts in infectious disease, epidemiology, and public health.

Public Mistrust May Undermine HPV and COVID-19 Vaccines

July 14th 2020

These are disquieting times for clear and decisive messaging regarding vaccines.

Precision Medicine Should Play a Role in Population-Based Health Care

July 1st 2020

Precision medicine should be seen as being synergistic―or at a minimum additive―to population medicine.

Profusion of New Drugs Prompts Need for Pragmatic Clinical Trials

June 15th 2020

The explosion of COVID-19 studies illustrates questions that have plagued oncology research.

Pandemic Poses a Crucial Moment for Science and the Public Trust

June 2nd 2020

At this moment, we should consider what it will take for the scientific community as a collective entity to self-regulate far more forcefully so that the actions of a limited number of its members do not squander the well-deserved awakening of public trust in the entire scientific enterprise.

Oncology Clinical Trials Should Reflect Molecular Advances, Real-World Patients

May 11th 2020

From the earliest moments of medical school instruction, through residency and fellowship training, physicians are taught the primacy of the randomized phase 3 trial in the hierarchy of evidence-based medicine.

Oncology Clinical Trials Should Reflect Molecular Advances, Real-World Patients

May 11th 2020

From the earliest moments of medical school instruction, through residency and fellowship training, physicians are taught the primacy of the randomized phase 3 trial in the hierarchy of evidence-based medicine.

COVID-19 Pandemic Exposes Faults in System, But May Prompt Advances in Telehealth and Research

April 21st 2020

What was simply unimaginable just a few weeks earlier regarding the potential impact of an infectious illness in the United States on jobs, schools, the economy, and personal and family safety has become a stream of daily pronouncements about the severity of the pandemic and how best to respond.

Unique Aspects of Cancer Surgery Make Clinical Trials Challenging

April 7th 2020

The conduct of randomized trials in surgical oncology, although highly appealing in concept, may be problematic, especially in complex settings where the skills, experience, and clinical judgment of individual surgeons and their institutions may vary greatly.

NEXT PAGE
PREVIOUS PAGE